论文部分内容阅读
艾司洛尔(ASL-8052,Ⅰ),化学名为4-〔2-羟基-3-〔(1-甲基)乙胺基〕丙氧基〕苯丙酸甲酯盐酸盐。本品由杜邦公司研制的,1986年12月美国食品药物管理局首次批准本品用于短期治疗室上性心动过速,次年在美国以商品名Brevibloc投放市场。艾司洛尔是一种静脉注射的β-阻滞剂,其特点是起效快,给药5分钟即生效作用可以调节,半衰期为9分钟,停药后作用消失亦快,可避免现有β-阻滞剂的缺点。本品连续输注给药,适用于中度心脏功能异常危象的
Esmolol (ASL-8052, I) chemically named methyl 4- [2-hydroxy-3 - [(1 -methyl) ethylamino] propoxy] benzenepropanoic acid methyl ester hydrochloride. This product was developed by DuPont, December 1986 the FDA approved the goods for the first time for the treatment of supraventricular tachycardia, the following year in the United States under the trade name Brevibloc market. Esmolol is an intravenous β-blocker characterized by rapid onset of action, modulation of 5-minute efficacy, half-life of 9 minutes, rapid disappearance of effects, and elimination of existing Disadvantages of beta-blockers. Continuous infusion of this product for moderate abnormalities in heart function crisis